Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn:
“BRIGHT-2 Final Analysis (JAMA Oncology)
Another player enters the CDK space.
Bireociclib (CDK2/4/6/9 inhibitor) + fulvestrant showed:
- PFS: 14.7 vs 7.3 months (HR 0.54).
- ORR: 45.6% vs 14.9%.
All in HR+/HER2- advanced breast cancer post-endocrine therapy
Quick Takeaways:
- Another CDK inhibitor with a broader target profile (CDK2/9 included).
- Signal looks solid – consistent benefit across subgroups.
- Safety profile largely in line with existing CDK4/6 inhibitors.
But…
- Compared against fulvestrant alone – limits how practice-changing this is.
- Hard to differentiate vs established options (ribociclib, abemaciclib, palbociclib).
- Raises the ongoing question: do we need more CDKs with oral SERD combos now more common, or better ways to predict who benefits from recycling of a CDK inhibitor?
Approved in China – global relevance TBD.
Curious how others are thinking about this space as it gets increasingly crowded.”
Title: Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression
Authors: Jiayu Wang, Qingyuan Zhang, Huiping Li, Zhongsheng Tong, Quchang Ouyang, Huihui Li, Yuee Teng, Biyun Wang, Tao Sun, Jingfen Wang, Wei Li, Zhaofeng Niu, Hongsheng Li, Chang Gong, Shu Wang, Xinshuai Wang, Xinhong Wu, Ning Liu, Guohua Yu, Yan Hu, Qiuli Wang, Xianghui Duan, Fan Yang, Li Wang, Binghe Xu
Read The Full Article
Other articles about Breast Cancer on OncoDaily.